Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer

<p><i>Anti-DCLK1 mAb inhibits pancreatic tumor growth in KPC mice</i>. Biweekly injection of CBT-15 mAb (<i>i.p.</i>) significantly impairs pancreatic tumor growth (p&lt;0.002) in KPC mice (n=4 in each group). (a) Average tumor volumes. (b) Individual tumor volumes.</p>

Journal of Oncology

fig6

Figure 6

Figure 6: Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer 

Figure 6 | Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer 